USSTOCK.TODAY
Pre-Market
Log in Sign up

AbbVie confirms efficacy of combination therapy in Phase 2 trial of Crohn's disease treatment ABBV-466

The Motley Fool +1 · ·by G4L

ABBV Abbvie Inc
$293.30 +0.68%
View chart & analysis →
  1. 1ABBV-466 induced more patients into remission during the Phase 2 clinical trial.
  2. 2At week 12, 30.2% of patients treated with the combination therapy reached endoscopic remission.
  3. 3BMO Capital Markets analysts assessed these results as positive for AbbVie stock.

So what's the key point?

AbbVie confirmed that patient conditions improved when using a new combination therapy. Experts evaluate this result as good news for AbbVie stock.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Allergan Aesthetics Announces Phase 4 Clinical Study Results for Adults Taking GLP-1 InvestorsHub +1 · 12h agoAbbVie signs $757 million licensing deal with Bryce Pharma for migraine treatment Pharmaceutical Technology · 5d agoAbbVie reports third-quarter results beating estimates and announces dividend increase The Motley Fool +1 · Oct 31
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news